Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer

IF 9.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-11-01 DOI:10.1016/j.bbcan.2024.189221

Ruomeng Bi , Li Chen , Mei Huang , Zhi Qiao , Zhen Li , Gaofeng Fan , Yu Wang

{"title":"Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer","authors":"Ruomeng Bi , Li Chen , Mei Huang , Zhi Qiao , Zhen Li , Gaofeng Fan , Yu Wang","doi":"10.1016/j.bbcan.2024.189221","DOIUrl":null,"url":null,"abstract":"<div><div>The utilization of PARP inhibitors (PARPis) has significantly improved the prognosis for ovarian cancer patients. However, as the use of PARPis increases, the issue of PARPi resistance has become more prominent. Prolonged usage of PARPis can lead to the development of resistance in ovarian cancer, often mediated by mechanisms such as homologous recombination (HR) recovery, ultimately resulting in cancer relapse. Overcoming PARPi resistance in ovarian cancer is a pressing concern, aiming to enhance the clinical benefits of PARPi treatment and delay disease recurrence. Here, we summarize the mechanisms underlying PARPi resistance, methods for analyzing resistance, and strategies for overcoming it. Our goal is to inspire the development of more cost-effective and convenient methods for analyzing resistance mechanisms, as well as safer and more effective strategies to overcome resistance. These advancements can contribute to developing personalized approaches for treating ovarian cancer.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189221"},"PeriodicalIF":9.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Reviews on cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304419X24001525","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The utilization of PARP inhibitors (PARPis) has significantly improved the prognosis for ovarian cancer patients. However, as the use of PARPis increases, the issue of PARPi resistance has become more prominent. Prolonged usage of PARPis can lead to the development of resistance in ovarian cancer, often mediated by mechanisms such as homologous recombination (HR) recovery, ultimately resulting in cancer relapse. Overcoming PARPi resistance in ovarian cancer is a pressing concern, aiming to enhance the clinical benefits of PARPi treatment and delay disease recurrence. Here, we summarize the mechanisms underlying PARPi resistance, methods for analyzing resistance, and strategies for overcoming it. Our goal is to inspire the development of more cost-effective and convenient methods for analyzing resistance mechanisms, as well as safer and more effective strategies to overcome resistance. These advancements can contribute to developing personalized approaches for treating ovarian cancer.

查看原文本刊更多论文

克服卵巢癌 PARP 抑制剂耐药性的新策略。

PARP 抑制剂（PARPis）的使用大大改善了卵巢癌患者的预后。然而，随着 PARPis 使用量的增加，PARPi 耐药性问题也日益突出。长期使用 PARPis 可导致卵巢癌耐药性的产生，通常由同源重组（HR）恢复等机制介导，最终导致癌症复发。克服卵巢癌中的PARPi耐药性是一个亟待解决的问题，其目的是提高PARPi治疗的临床疗效并延缓疾病复发。在此，我们总结了 PARPi 耐药性的机制、分析耐药性的方法以及克服耐药性的策略。我们的目标是鼓励开发更经济、更便捷的耐药性机制分析方法，以及更安全、更有效的耐药性克服策略。这些进展有助于开发治疗卵巢癌的个性化方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochimica et biophysica acta. Reviews on cancer 医学-生化与分子生物学

CiteScore

17.20

自引率

0.00%

发文量

138

审稿时长

33 days

期刊介绍： Biochimica et Biophysica Acta (BBA) - Reviews on Cancer encompasses the entirety of cancer biology and biochemistry, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signaling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. It publishes mini-reviews and full reviews.